Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Efez vs INSPRA (Eplerenone) in Healthy Subjects
NCT05663372Phase 1Completed
- Sponsor
- Darnitsa
- Start
- Dec 2021
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eplerenone in hypertension (HTN) and heart failure (HF) (2 arms), sponsored by Darnitsa. Primary endpoints: Maximum Plasma Concentration and Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration. Started Dec 2021; status: completed.
02
Drugs
eplerenone
03
Conditions
hypertension (HTN)heart failure (HF)
Beyond the preview
Go deeper on NCT05663372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05663372.